Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Firefly Neuroscience (AIFF) Free Cash Flow (2016 - 2025)

Firefly Neuroscience has reported Free Cash Flow over the past 15 years, most recently at -$1.8 million for Q4 2025.

  • Quarterly results put Free Cash Flow at -$1.8 million for Q4 2025, down 40.83% from a year ago — trailing twelve months through Dec 2025 was -$8.3 million (down 32.03% YoY), and the annual figure for FY2025 was -$8.3 million, down 32.03%.
  • Free Cash Flow for Q4 2025 was -$1.8 million at Firefly Neuroscience, down from -$1.6 million in the prior quarter.
  • Over the last five years, Free Cash Flow for AIFF hit a ceiling of $491536.0 in Q3 2023 and a floor of -$2.9 million in Q4 2022.
  • Median Free Cash Flow over the past 5 years was -$1.3 million (2024), compared with a mean of -$1.3 million.
  • Biggest five-year swings in Free Cash Flow: skyrocketed 154.87% in 2021 and later plummeted 1337.98% in 2022.
  • Firefly Neuroscience's Free Cash Flow stood at -$322949.0 in 2021, then tumbled by 793.73% to -$2.9 million in 2022, then skyrocketed by 82.33% to -$510000.0 in 2023, then crashed by 154.51% to -$1.3 million in 2024, then tumbled by 40.83% to -$1.8 million in 2025.
  • The last three reported values for Free Cash Flow were -$1.8 million (Q4 2025), -$1.6 million (Q3 2025), and -$2.4 million (Q2 2025) per Business Quant data.